Regulus filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, which includes, among other things, the recommendation of Regulus’s board of directors that Regulus’s stockholders ...

Despite some declining revenues from established brands, Novartis' pipeline and recent performance suggest continued growth, with double-digit revenue and income growth expected in 2024.

Farabursen adds to Novartis' existing pipeline of kidney disease drugs, including those acquired through its $3.5 billion buyout of Chinook Therapeutics in 2023. Novartis has recently received U.S ...

Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline. CEO Vas Narasimhan said ...

1 This will add the potential kidney disease treatment to Novartis’ already expansive pipeline of treatments for renal disease. According to a press release from Novartis, the boards of both companies ...

Swiss pharma giant Novartis is re-entering the booming field of ageing research. It wants to develop a blockbuster drug in ...

Novartis has slimmed down its clinical-stage ... We took that data to heart and really wanted to rethink how we approach our pipeline.” “So we made a significant, nearly 40%, reduction in ...

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy ...

Novartis agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal means the Swiss pharmaceutical company ...

Novartis has announced that it will be acquiring Regulus Therapeutics in a deal worth $1.7bn, marking a notable boost to the drugmaker’s renal disease pipeline. The agreement will give Novartis access ...

Novartis' drug segment is poised for steady cash flows driven by new pipeline products and existing drugs. Novartis' strategy to focus largely in areas of unmet medical need should strengthen the ...

The leading Metastatic Merkel Cell Carcinoma Companies such as Incyte Corporation, Merck, Pfizer, Millennium Pharmaceuticals ...